Medical progress: Gastroesophageal variceal hemorrhage

New England Journal of Medicine

Volumn 345, Issue 9, 2001, Pages 669-681

  Sharara, Ala I ^a,b   Rockey, Don C ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ENBUCRILATE; GLYCERYL TRINITRATE; ISOSORBIDE MONONITRATE; MOLSIDOMINE; NADOLOL; NITRIC ACID DERIVATIVE; OCTREOTIDE; PENTOXIFYLLINE; PROPRANOLOL; SOMATOSTATIN; SPIRONOLACTONE; TERLIPRESSIN; VAPREOTIDE; VASOPRESSIN; VASOCONSTRICTOR AGENT;

ABDOMINAL PAIN; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ENDOSCOPIC SCLEROTHERAPY; ENDOSCOPIC SURGERY; ESOPHAGUS VARICES BLEEDING; HUMAN; HYPERGLYCEMIA; LIGATION; LIVER CIRRHOSIS; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; STOMACH VARICES; SURVIVAL; TREATMENT INDICATION; VASCULAR DISEASE; BALLOON DILATATION; COST BENEFIT ANALYSIS; ENDOSCOPY; ESOPHAGUS VARICES; GASTROINTESTINAL HEMORRHAGE; RECURRENT DISEASE; SCLEROTHERAPY;

ADRENERGIC BETA-ANTAGONISTS; BALLOON DILATATION; COST-BENEFIT ANALYSIS; ENDOSCOPY; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; PORTASYSTEMIC SHUNT, SURGICAL; RECURRENCE; SCLEROTHERAPY; VASOCONSTRICTOR AGENTS;

EID: 0035975323     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra003007     Document Type: Review

References (111)

1. Upper gastrointestinal tract hemorrhage
2. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: A prospective multicenter study
3. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage
4. Prospective evaluation of esophageal varices in primary biliary cirrhosis: Development, natural history, and influence on survival
5. The economic impact of esophageal variceal hemorrhage: Cost-effectiveness implications of endoscopic therapy
6. Natural history and prognosis of variceal bleeding
7. Endoscopic scleropathy versus portacaval shunt in patients with severe cirrhosis and acute variceal hemorrhage: Long-term follow-up
8. The course of patients after variceal hemorrhage
9. The mortality of bleeding esophageal varices in a private university hospital
10. Cellular localization of endothelin-1 and increased production in liver injury in the rat: Potential for autocrine and paracrine effects on stellate cells
11. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension
12. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats
13. Hemodynamic factors involved in the development and rupture of esophageal varices: A pathophysiologic approach to treatment
14. Portal pressure, presence of gastroesophageal varices and variceal bleeding
15. Hemodynamic evaluation of patients with intrahepatic portal hypertension: Relationship between bleeding varices and the portohepatic gradient
16. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis
17. Gastroesophageal endoscopic features in cirrhosis: Observer variability, interassociations, and relationship to hepatic dysfunction
18. Prediction of variceal hemorrhage by esophageal endoscopy
19. Transection of the oesophagus for bleeding oesophageal varices
20. Direct transhepatic measurement of portal vein pressure using a thin needle: Comparison with wedged hepatic vein pressure
21. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: A 10-year prospective study
22. Prognostic value of early measurements of portal pressure in acute variceal bleeding
23. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis
24. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices: An analysis of data and prognostic factors in 589 patients from four randomized clinical trials
25. Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease: A randomized, single-blind, multicenter clinical trial
26. Pharmacological treatment of portal hypertension: An evidence-based approach
27. Predictors of large esophageal varices in patients with cirrhosis
28. Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection?
29. Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function
30. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis
31. Effects of molsidomine, a long acting venous dilator, on portal hypertension: A hemodynamic study in patients with cirrhosis
32. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage
33. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis
34. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding
35. Short-term effects of propranolol on portal venous pressure
36. The effect of propranolol on portal hypertension in patients with cirrhosis: A hemodynamic study
37. Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis
38. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices
39. Nadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis: A randomized trial
40. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial
41. Prevention of first bleeding in cirrhosis: A meta-analysis of randomized trials of nonsurgical treatment
42. Primary prophylaxis of variceal bleeding in cirrhosis: A cost-effectiveness analysis
43. Isosorbide dinitrate in experimental portal hypertension: A study of factors that modulate the hemodynamic response
44. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: Implications for therapy
45. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis
46. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis
47. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: A randomized controlled study
48. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis
49. Propranolol versus sclerotherapy in preventing variceal rebleeding: A randomized controlled trial
50. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding
51. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients
52. Early administration of vapreotide for variceal bleeding in patients with cirrhosis
53. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage
54. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta-analysis
55. Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: A prospective, controlled clinical trial
56. Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo-controlled clinical trial
57. A randomized trial ofvasopressin and vasopressin plus nitroglycerin in the control of acute variceal hemorrhage
58. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: The TEST study
59. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage
60. A multicentre randomised trial comparing octreotide and injection sclerotherapy in the management and outcome of acute variceal haemorrhage
61. Octreotide infusion or emergency sclerotherapy for variceal haemorrhage
62. Sclerotherapy with or without octreotide for acute variceal bleeding
63. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation
64. Controlled clinical trial of injection sclerotherapy for active variceal bleeding
65. Injection sclerotherapy preceded by esophageal tamponade versus immediate sclerotherapy in arresting active variceal bleeding: A prospective randomized trial
66. A comparison of sclerotherapy with staple transection of the esophagus for the emergency control of bleeding from esophageal varices
67. Endoscopic ligation compared with sclerotherapy for the treatment of bleeding esophageal varices
68. Emergency banding ligation versus sclerotherapy for the control of active bleeding from esophageal varices
69. Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices
70. Endoscopic treatment of bleeding gastric varices by N-butyl-2-cyanoacrylate (Histoacryl) injection: Long-term efficacy and safety
71. Emergency endoscopic ligation of actively bleeding varices with a detachable snare
72. A randomized trial of terlipressin plus nitroglycerin vs. balloon tamponade in the control of acute variceal hemorrhage
73. A comparative study of emergency transjugular intrahepatic portosystemic stent-shunt and esophageal transection in the management of uncontrolled variceal hemorrhage
74. Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy
75. Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting
76. Prospective randomized trial of emergency portacaval shunt and emergency medical therapy in unselected cirrhotic patients with bleeding varices
77. Variceal hemorrhage: A critical evaluation of survival analysis
78. Sclerotherapy after first variceal hemorrhage in cirrhosis: A randomized multi-center trial
79. Why do varices bleed?
80. Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepatic gradient
81. Controlled trial ofpropranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis
82. Propranolol for the prevention of recurrent variceal hemorrhage: A controlled trial
83. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A final report
84. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta-analysis
85. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding
86. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding
87. A prospective, randomized trial of sclerotherapy versus ligation in the management of bleeding esophageal varices
88. Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: A meta-analysis
89. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: A meta-analysis
90. Propranolol reduces the rebleeding rate during endoscopic sclerotherapy before variceal obliteration
91. Propranolol in the prevention of recurrent upper gastrointestinal bleeding in patients with cirrhosis undergoing endoscopic sclerotherapy: A randomized controlled trial
92. Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: A prospective, randomized trial
93. Endoscopic variceal ligation is superior to combined ligation and sclerotherapy for esophageal varices: A multicenter prospective randomized trial
94. Randomized comparison of ligation versus ligation plus sclerotherapy in patients with bleeding esophageal varices
95. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage: A randomized, controlled trial
96. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices
97. Randomised trial of transjugular-intrahepatic-portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding
98. Transjugular intrahepatic portosystemic shunt and hepatic encephalopathy
99. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study
100. Transjugular intrahepatic portosystemic shunt in patients with end-stage liver disease: Results in 85 patients
101. Analysis of prognostic variables in the prediction of mortality, shunt failure, variceal rebleeding and encephalopathy following the transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage
102. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: Results in 90 patients
103. Transjugular intrahepatic portosystemic shunt stenosis and revision: Early and midterm results
104. The inaccuracy of duplex ultrasonography in predicting patency of transjugular intrahepatic portosystemic shunts
105. Cost analysis for the prevention of variceal rebleeding: A comparison between transjugular intrahepatic portosystemic shunt and endoscopic sclerotherapy in a selected group of Italian cirrhotic patients
106. Role of distal splenorenal shunt for long-term management ofvariceal bleeding
107. Distal spleno-renal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding: A meta-analysis of 4 randomized clinical trials
108. Vasoconstrictors in the management of bleeding from oesophageal varices: A clinico-economic appraisal in the United Kingdom
109. Resource analysis of somatostatin in the treatment of bleeding esophageal varices
110. Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding
111. Cost of treatment of bleeding esophageal varices